Imatinib administration in two patients with liver metastases from GIST and severe jaundice.
Imatinib is the only effective and approved systemic therapy for the treatment of patients with advanced gastrointestinal stromal tumours (GISTs). Although metastases from GISTs most commonly involve the liver, yielding hyperbilirubinaemia, very few data on imatinib administration in subjects with jaundice are available. We provide evidence that imatinib tolerability was not adversely affected by jaundice in two patients with advanced GIST.
De Pas
T
T
Department of Medical Oncology, European Institute of Oncology, Via Ripamonti, 435, Milano 20141, Italy. tommaso.de-pas@ieo.it
Danesi
R
R
Catania
C
C
Curigliano
G
G
De Braud
F
F
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D001549:Benzamides; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000150:complications / Q000473:pathology*; D006801:Humans; D000068877:Imatinib Mesylate; D007565:Jaundice / Q000209:etiology*; D008113:Liver Neoplasms / Q000150:complications* / Q000556:secondary*; D008297:Male; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D017154:Stromal Cells / Q000473:pathology; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate